Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2015 2
2017 3
2018 4
2019 8
2020 9
2021 10
2022 15
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. Kotecha RR, et al. Among authors: kuo f. Cancer. 2024 Mar 1;130(5):692-701. doi: 10.1002/cncr.35074. Epub 2023 Oct 21. Cancer. 2024. PMID: 37864521
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Vos JL, Burman B, Jain S, Fitzgerald CWR, Sherman EJ, Dunn LA, Fetten JV, Michel LS, Kriplani A, Ng KK, Eng J, Tchekmedyian V, Haque S, Katabi N, Kuo F, Han CY, Nadeem Z, Yang W, Makarov V, Srivastava RM, Ostrovnaya I, Prasad M, Zuur CL, Riaz N, Pfister DG, Klebanoff CA, Chan TA, Ho AL, Morris LGT. Vos JL, et al. Among authors: kuo f. Nat Med. 2023 Dec;29(12):3077-3089. doi: 10.1038/s41591-023-02518-x. Epub 2023 Aug 24. Nat Med. 2023. PMID: 37620627 Clinical Trial.
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Novoplansky O, Shnerb AB, Marripati D, Jagadeeshan S, Abu Shareb R, Conde-López C, Zorea J, Prasad M, Ben Lulu T, Yegodayev KM, Benafsha C, Li Y, Kong D, Kuo F, Morris LGT, Kurth I, Hess J, Elkabets M. Novoplansky O, et al. Among authors: kuo f. Mol Oncol. 2023 Dec;17(12):2618-2636. doi: 10.1002/1878-0261.13500. Epub 2023 Aug 31. Mol Oncol. 2023. PMID: 37501404 Free PMC article.
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.
Tang C, Xie AX, Liu EM, Kuo F, Kim M, DiNatale RG, Golkaram M, Chen YB, Gupta S, Motzer RJ, Russo P, Coleman J, Carlo MI, Voss MH, Kotecha RR, Lee CH, Tansey W, Schultz N, Hakimi AA, Reznik E. Tang C, et al. Among authors: kuo f. Cell Metab. 2023 Aug 8;35(8):1424-1440.e5. doi: 10.1016/j.cmet.2023.06.005. Epub 2023 Jul 5. Cell Metab. 2023. PMID: 37413991 Free article.
Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma.
Chakiryan NH, Kim Y, Berglund A, Chang A, Kimmel GJ, Hajiran A, Nguyen J, Moran-Segura C, Saeed-Vafa D, Katende EN, Lopez-Blanco N, Chahoud J, Rappold P, Spiess PE, Fournier M, Jeong D, Wang L, Teer JK, Dhillon J, Kuo F, Hakimi AA, Altrock PM, Mulé JJ, Manley BJ. Chakiryan NH, et al. Among authors: kuo f. J Immunother Cancer. 2023 Apr;11(4):e006195. doi: 10.1136/jitc-2022-006195. J Immunother Cancer. 2023. PMID: 37185232 Free PMC article.
55 results